Related references
Note: Only part of the references are listed.Diminished muscle oxygen uptake and fatigue in spinal muscular atrophy
Jacqueline Montes et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)
MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients
Claudia Brogna et al.
JOURNAL OF NEUROLOGY (2020)
Twenty-Five Years of Spinal Muscular Atrophy Research: From Phenotype to Genotype to Therapy, and What Comes Next
Brunhilde Wirth et al.
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 21, 2020 (2020)
Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients
Irene Faravelli et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Muscle-specific SMN reduction reveals motor neuron-independent disease in spinal muscular atrophy models
Jeong-Ki Kim et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience
Aravindhan Veerapandiyan et al.
MUSCLE & NERVE (2020)
Overturning the Paradigm of Spinal Muscular Atrophy as Just a Motor Neuron Disease
Crystal Jing Jing Yeo et al.
PEDIATRIC NEUROLOGY (2020)
Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study
Tim Hagenacker et al.
LANCET NEUROLOGY (2020)
Progression and prognosis in multiple system atrophy presenting with REM behavior disorder
Giulia Giannini et al.
NEUROLOGY (2020)
Longitudinal natural history of type I spinal muscular atrophy: a critical review
Eugenio Mercuri et al.
ORPHANET JOURNAL OF RARE DISEASES (2020)
Clinical Variability in Spinal Muscular Atrophy TypeIII
Giorgia Coratti et al.
ANNALS OF NEUROLOGY (2020)
Muscle strength and motor function in adolescents and adults with spinal muscular atrophy
Camiel A. Wijngaarde et al.
NEUROLOGY (2020)
Nusinersen in adult patients with spinal muscular atrophy Observations from a single center
Orly Moshe-Lilie et al.
NEUROLOGY (2020)
Lack of effect on ambulation of dalfampridine-ER (4-AP) treatment in adult SMA patients
Claudia A. Chiriboga et al.
NEUROMUSCULAR DISORDERS (2020)
Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3
Lorenzo Maggi et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Muscle MRI in two SMA patients on nusinersen treatment: A two years follow-up
Andrea Barp et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2020)
Measuring Outcomes in Adults with Spinal Muscular Atrophy - Challenges and Future Directions - Meeting Report
V. A. Sansone et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2020)
Advances in Treatment of Spinal Muscular Atrophy - New Phenotypes, New Challenges, New Implications for Care
David C. Schorling et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2020)
Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy
Crystal Jing Jing Yeo et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2020)
FIREFISH Part 2: Efficacy and safety of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA)
Giovanni Baranello et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen
Elisabeth Jochmann et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2020)
Revised upper limb module for spinal muscular atrophy: 12 month changes
Maria Carmela Pera et al.
MUSCLE & NERVE (2019)
NFL is a marker of treatment response in children with SMA treated with nusinersen
Bob Olsson et al.
JOURNAL OF NEUROLOGY (2019)
Neurofilament as a potential biomarker for spinal muscular atrophy
Basil T. Darras et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data
Marika Pane et al.
ANNALS OF NEUROLOGY (2019)
Fast skeletal muscle troponin activator CK-2066260 increases fatigue resistance by reducing the energetic cost of muscle contraction
Arthur J. Cheng et al.
JOURNAL OF PHYSIOLOGY-LONDON (2019)
Long-term progression in type II spinal muscular atrophy A retrospective observational study
Eugenio Mercuri et al.
NEUROLOGY (2019)
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
Darryl C. De Vivo et al.
NEUROMUSCULAR DISORDERS (2019)
Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy
Didu S. T. Kariyawasam et al.
FRONTIERS IN NEUROLOGY (2019)
Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen
Andreas Totzeck et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1
Omar Dabbous et al.
ADVANCES IN THERAPY (2019)
Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment
Claudia D. Wurster et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy
Kimberly K. Long et al.
HUMAN MOLECULAR GENETICS (2019)
Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3-A Prospective Observational Study
Maggie C. Walter et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2019)
Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics
Richard S. Finkel et al.
NEUROMUSCULAR DISORDERS (2018)
Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases
Maite Calucho et al.
NEUROMUSCULAR DISORDERS (2018)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression
Jacqueline Montes et al.
PLOS ONE (2018)
Patient Reported Impact of Symptoms in Spinal Muscular Atrophy (PRISM-SMA)
Phillip Mongiovi et al.
NEUROLOGY (2018)
Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs
Agnes Poirier et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2018)
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
J. R. Mendell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Longitudinal characterization of biomarkers for spinal muscular atrophy
Ulrike Bonati et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2017)
Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset
Zhihua Feng et al.
HUMAN MOLECULAR GENETICS (2016)
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials
Eugenio Mercuri et al.
NEUROMUSCULAR DISORDERS (2016)
Impaired Muscle Mitochondrial Biogenesis and Myogenesis in Spinal Muscular Atrophy
Michela Ripolone et al.
JAMA NEUROLOGY (2015)
Fast Skeletal Muscle Troponin Activator tirasemtiv Increases Muscle Function and Performance in the B6SJL-SOD1G93A ALS Mouse Model
Darren T. Hwee et al.
PLOS ONE (2014)
Prospective cohort study of spinal muscular atrophy types 2 and 3
Petra Kaufmann et al.
NEUROLOGY (2012)
Spinal Muscular Atrophy A Timely Review
Stephen J. Kolb et al.
ARCHIVES OF NEUROLOGY (2011)
Spinal muscular atrophy
Adele D'Amico et al.
ORPHANET JOURNAL OF RARE DISEASES (2011)
Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)
Allan M. Glanzman et al.
PEDIATRIC PHYSICAL THERAPY (2011)
Newborn and Carrier Screening for Spinal Muscular Atrophy
Thomas W. Prior et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2010)
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Yimin Hua et al.
GENES & DEVELOPMENT (2010)
The c.859G > C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor
S. Bernal et al.
JOURNAL OF MEDICAL GENETICS (2010)
Systemic Delivery of scAAV9 Expressing SMN Prolongs Survival in a Model of Spinal Muscular Atrophy
Chiara F. Valori et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Genetic risk assessment in carrier testing for spinal muscular atrophy
S Ogino et al.
AMERICAN JOURNAL OF MEDICAL GENETICS (2002)
Share Paper
